-
公开(公告)号：EP3195867B1
公开(公告)日：2019-09-04
申请号：EP17158250.5
申请日：2012-02-27
申请人： Ustav organicke chemie a biochemie Akademie ved CR, v.v.i. , Ustav experimentalni mediciny Akademie ved CR, v.v.i.
发明人： Jansa, Petr , Holy, Antonin , Zidek, Zdenek , Kmonickova, Eva , Janeba, Zlatko
IPC分类号： A61K31/505 , A61K31/506 , C07D239/20 , C07D239/34 , C07D239/36 , C07D239/38 , C07D239/42 , C07D401/04 , C07D403/04 , C07D405/04 , C07D409/04 , A61P29/00 , A61P35/00 , A61P37/00
-
2.发明公开PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF 审中-公开嘧啶用于抑制氮氧化物的前列腺素E2的形成，生产和使用方法发明
公开(公告)号：EP2680847A1
公开(公告)日：2014-01-08
申请号：EP12710650.8
申请日：2012-02-27
申请人： Ustav Organicke Chemie A Biochemie Akademie Ved Cr, v.v.i. , Ustav Experimentalni Mediciny Akademie Ved Cr, v.v.i.
发明人： JANSA, Petr , HOLY, Antonin , ZIDEK, Zdenek , KMONICKOVA, Eva , JANEBA, Zlatko
IPC分类号： A61K31/505 , A61K31/506 , C07D239/20 , C07D239/34 , C07D239/36 , C07D239/38 , C07D239/42 , C07D401/04 , C07D403/04 , C07D405/04 , C07D409/04 , A61P29/00 , A61P35/00 , A61P37/00
CPC分类号： C07D239/24 , A61K31/505 , A61K31/506 , C07D239/20 , C07D239/34 , C07D239/38 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D409/04
摘要： The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided.
-
3.发明公开
公开(公告)号：EP3582787A1
公开(公告)日：2019-12-25
申请号：EP18754040.6
申请日：2018-02-13
-
4.发明公开PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF 审中-公开抑制一氧化氮和前列腺素E2形成的嘧啶化合物，其制备方法及其用途
公开(公告)号：EP3195867A1
公开(公告)日：2017-07-26
申请号：EP17158250.5
申请日：2012-02-27
申请人： Ustav Organicke Chemie A Biochemie Akademie Ved Cr, v.v.i. , Ustav Experimentalni Mediciny Akademie Ved Cr, v.v.i.
发明人： Jansa, Petr , Holy, Antonin , Zidek, Zdenek , Kmonickova, Eva , Janeba, Zlatko
IPC分类号： A61K31/505 , A61K31/506 , C07D239/20 , C07D239/34 , C07D239/36 , C07D239/38 , C07D239/42 , C07D401/04 , C07D403/04 , C07D405/04 , C07D409/04 , A61P29/00 , A61P35/00 , A61P37/00
CPC分类号： C07D239/24 , A61K31/505 , A61K31/506 , C07D239/20 , C07D239/34 , C07D239/38 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D409/04
摘要： The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided.
摘要翻译： 本发明提供通式（I）的嘧啶化合物，其同时减少一氧化氮（NO）和前列腺素E2（PGE 2）的产生。 它们对细胞活力没有负面影响，其浓度将这些因子的产量降低高达50％; 它们不具有细胞毒性。 此外，制备通式（I）的嘧啶化合物的方法，其携带2-甲酰胺基，包含本发明的取代的嘧啶化合物的药物组合物，以及这些化合物用于治疗炎性和癌症疾病的用途 被提供。
-
-
-
搜索结果
4 条记录 (耗时 0.011 秒)
